Home
Clinical Trials
Study Evaluating Three Bazedo...

Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution

Last Updated: 2015-05-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-08-31

Study Completion Date

2006-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study involves the experimental drug bazedoxifene acetate/conjugated estrogens (also called BZA/CE). This drug is not approved by the Food and Drug Administration (FDA).

About 24 subjects will take part in this study. Each subject's participation in this study will last for about 10 weeks. During this study, each subject will receive 3 different types of BZA/CE tablets plus an oral solution containing only BZA. The purpose of this study is to learn how the tablet dosage forms dissolve and are absorbed by the body compared to the BZA oral solution. In addition, information will also be learned about the safety and tolerability of these dosage forms given to healthy postmenopausal women.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms

NCT00479778

Postmenopause

COMPLETED PHASE1

A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women

NCT01634789

Healthy

TERMINATED PHASE1

Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women

NCT00464789

Menopause

COMPLETED PHASE1

Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens

NCT00550303

Healthy

COMPLETED PHASE1

Study Evaluating Bazedoxifene/CE in Postmenopausal Women

NCT00550433

Postmenopause

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postmenopause

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bazedoxifene/conjugated estrogens combination tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Generally healthy, nonsmoking (or smoker of less than 10 cigarettes/day)
* Postmenopausal women aged 35 to 70 years
* At least 12 months of spontaneous amenorrhea, OR 6 months of spontaneous amenorrhea with follicle-stimulating hormone (FSH) levels at least 38 mIU/mL
* Women 55 years of older must have at least 12 months of amenorrhea
* Body mass index in the range of 18.0 to 35.0, with a minimum body weight of 50 kg

Exclusion Criteria

* A history or active presence of clinically important medical disease.
* History or alcoholism or drug abuse within 1 year before study start.
* Use of estrogen-, androgen-, or progestin-containing medication by a non-oral route of administration within 6 months before study day 1 must be approved by Wyeth Research

Minimum Eligible Age

35 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes